Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
torudokimab
- Development stage
- Phase 2
- Lead developer
- Zura Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Torudokimab is a fully human monoclonal antibody that specifically targets and neutralizes interleukin-33 (IL-33), a cytokine involved in inflammatory and immune responses. It does not bind to other members of the IL-1 family and demonstrates high affinity for human and cynomolgus monkey IL-33, but not for mouse, rat, or rabbit IL-33. Torudokimab was originally developed by Eli Lilly and is now being further developed by Zura Bio under license. The drug has been investigated primarily for atopic dermatitis (where development was discontinued) and is currently in Phase 2 clinical trials for asthma. Its mechanism of action involves inhibiting the activity of IL-33, thereby modulating inflammatory pathways relevant to diseases such as asthma[2][4][10].
- Brand names
- torudokimab
- Other names
- IL-33 antibody - Zura BioIL33 antibody - Zura BioIL 33 antibody - Zura BioAnti-IL-33Anti-IL33Anti-IL 33
02
Targets
IL33 (IL-33)
Beyond the preview
Go deeper on torudokimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on torudokimab.